Head and Neck Cancer Market Size

Global Head and Neck Cancer Market Overview

The head and neck cancer market size was valued at USD 1.18 Billion in 2023. The head and neck cancer industry is anticipated to grow from USD 1.26 Billion in 2024 to USD 2.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.45% during the forecast period (2024 - 2032). The rising majority of head and neck cancer, different government initiatives for varied cancer therapy developments, and growing awareness among people concerning progressive cancer treatments are the key market drivers expanding the market growth.

Source Primary Research, MRFR Database, Secondary Research, and Analyst Review

In December 2023 saw the announcement by Exelixis, Inc. that they had launched STELLAR-305, a phase 2/3 trial to study the combination of zanzalintinib with pembrolizumab versus pembrolizumab for head and neck cancer patients.

Pierre Fabre S.A. joined forces with Vernalis Research (Subsidiary of HitGen Inc.) in September 2023 to participate in the oncology drug development program.

Merck & Co., Inc. disclosed favorable clinical results from its LEAP-010 experimental study in August 2023, intended to provide treatment for metastatic and recurrent head & neck cancer. The company began the research in collaboration with Eisai.

In May 2023, Bristol-Myers Squibb Company signed a strategic partnership with The Swallows Head & Neck Cancer Support Charity, aiming at providing care to patients who are suffering from cancer.

Take for instance, LG Chem, which bought AVEO Oncology between October and January 2022 so as to establish itself as a top oncology company with the solid clinical pipeline. This deal can hasten go-to-market launch of anti-cancer medicines by harnessing AVEO’s strong preclinical and later-stage clinical portfolios alongside LG Chem’s R&D strengths in oncology sector. As this move expands LG Chem’s reach into a wider patient population, it broadens out its pipeline by immersing it into other indications, too, thereby building an improved ability to make innovative advanced malignancy therapies available more than ever before.

In April 2020, Cue Biopharma entered into a strategic alliance with Merck over an injectable combination of Keytruda (pembrolizumab) and CUE-101 that could be used against HPV-positive Head & Neck cancer.

Head and Neck Cancer Market Trends

• The rise in the burden of cancer is driving the market growth

Market CAGR for head and neck cancer is driven by the growing burden of head and neck cancer worldwide. Head and neck cancer refers to numerous types of cancers that affect your mouth, throat or other parts of the head and neck. For instance, As per the data issued by the American Society of Clinical Oncology, head and neck cancer is the seventh most expected cancer ly, with 1.1 million new diagnoses reported annually. In 2020, more than 562,328 people worldwide were diagnosed with head and neck cancer, and around 277,597 died.

Additionally, the existence of a strong product pipeline and their anticipated launch will contribute to market growth. Some of the developments in the pipeline are tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Tipifarnib (Farnesyltransferase Inhibitor), Rozlytrek (entrectinib), and Afatinib. Prosperous completion of tests and successive approval is anticipated to drive market growth. For instance, in February 2021, the U.S. FDA granted a breakthrough therapy appointment to Tipifarnib, designed by Kura Oncology, Inc., for treating patients with head and neck squamous cell carcinoma. This is a potent, particular, and orally administered drug.

The demand for immunotherapy is rising among head and neck cancer patients, owing to the increasing awareness regarding the benefits of immunotherapy drugs over traditional chemotherapy. Chemotherapy involves various risks, such as reoccurrence of cancer, high side effects, loss of life, and organ failure. Immunotherapy has no or low side effects and provides effective treatment. This is boosting the demand for immunotherapy drugs among patients across the globe, driving the head and neck cancer market revenue.

Moreover, in the recent few years, the prominent players are actively involving themselves in various strategic measures which are positively affecting the market growth. For instance, in December 2021, Sanofi SA announced the acquisition of Amu nix Pharmaceuticals, Inc., to boost and expand its oncology portfolio. The former will leverage the latter’s clinically proven XTEN, and Pro-XTEN technologies, for the discovery and development of transformative T-cell engagers and cytokine-based therapies for the treatment of head and neck cancer.

Head and Neck Cancer Market Segment Insights

Head and Neck Cancer Type Insights

The head and neck cancer market segmentation, based on type, includes laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip & oral cavity cancer, nasopharyngeal cancer, and others. The laryngeal cancer segment dominated the market, accounting for 35% of market revenue (0.41 Billion). In developing economies, category growth is driven by an increased incidence of cigarette smoking. However, salivary gland cancer is the fastest-growing category due to growing government initiatives and advancements in treatment options.

Head and Neck Cancer Diagnosis Insights

The head and neck cancer market segmentation, based on diagnosis, includes bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy. The blood tests category generated the most income (70.4%) due to several research studies being carried out ly by research organizations and major players. However, endoscopy is the fastest-growing category due to cost-effective pre and post-procedures and increasing awareness of minimal invasive properties.

Head and Neck Cancer Treatment Insights

The head and neck cancer market segmentation, based on treatment, includes chemotherapy, surgery, radiation therapy, targeted therapy, and others. The targeted therapy category generated the most income due to promising and effective results related to the usage of targeted therapy as a treatment option for head and neck cancer patients. However, chemotherapy is the fastest-growing category due to the growing burden of head and neck cancer across the globe. Chemotherapy treats head and neck cancer and uses powerful drugs to attack cancer cells.

Head and Neck Cancer End-User Insights

The head and neck cancer market segmentation, based on end-user, includes hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital category generated the most income due to well-equipped infrastructure and better disease diagnosis. However, specialty clinics are the fastest-growing category due to the increasing number of cancer specialty clinics and favorable government projects for poor sections of the community.

Figure 1 Head and Neck Cancer Market by End-User, 2022 & 2032 (USD Billion)

Source Primary Research, MRFR Database, Secondary Research,  and Analyst Review

Head and Neck Cancer Regional Insights

By region, the study delivers market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American market will dominate owing to government support for the development of the healthcare sector, high awareness about the disease, favorable reimbursement policies, and easy accessibility to quality medical facilities will boost the market growth in this region. Further, the German head and neck cancer market held the largest market share, and the UK head and neck cancer mark,et was the fastest-growing market in the North American region.

Further, the prominent countries studied in the market report are The US, Canada, German France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 HEAD AND NECK CANCER MARKET SHARE BY REGION 2022 (USD Billion)

Source Primary Research, MRFR Database, Secondary Research, and Analyst Review

Europe head and neck cancer market accounts for the second-largest market share due to the increasing geriatric populations and rising prescription of immunotherapy drugs for the treatment of various types of head and neck cancer. Further, the German market held the largest market share, and the UK head and neck cancer drugs market was the fastest-growing market in the European region.

The Asia-Pacific head and neck cancer market is anticipated to grow at the fastest CAGR from 2024 to 2032. This is owing to the rising number of patients due to the rising smoking, tobacco, and alcohol-consuming population in this region. Moreover, China’s head and neck cancer market held the most extensive market share, and the Indian head and neck cancer market was the fastest-growing market in the Asia-Pacific region.

Head and Neck Cancer Key Market Players & Competitive Insights

Leading market participants are investing heavily in research and development to extend their product lines, which will allow the head and neck cancer market to grow even more. Market participants are also undertaking different strategic activities to extend their footprint, with significant market developments including new product establishments, higher investments, contractual deals, mergers and acquisitions, and collaboration with other organizations. To enhance and survive in a more competitive and growing market climate, the head and neck cancer industry must deliver cost-effective items.

Manufacturing locally to decrease operational costs is one of the key business tactics utilized by manufacturers in the  head and neck cancer industry to help clients and increase the market sector. Major market players in the global market, including Bayer Healthcare AG, Boston Biomedical, Inc., Bristol-Myers Squibb firm, Astellas Pharma Inc., AbbVie Inc, and others, are trying to increase market demand by investing in R&D operations.

Fulgent Genetics Inc is a provider of clinically diagnostic genetic testing and genetic information to physicians. The company offers a range of testing options through its proprietary technology platform that integrates genetic diagnostics tools with adaptive learning software, data comparison and suppression algorithms, and laboratory processes. Its major offerings include genes and panels, known mutation, genomic testing, hereditary cancer, carrier screening, tumor profiling, newborn genetics and covid-19 testing. It offers genetic tests for cardiovascular and pediatric diseases, neurological disorders, and cancers and primarily serves medical institutions and hospitals. In November 2022, Fulgent Genetics, Inc. announced the acquisition of Fulgent Pharma Holdings, Inc. to provide an integrated solution to combat head and neck cancer in the region.

PDS Biotechnology Corp works as a clinical-stage biotechnology company. The Company develops immuno-oncology therapies to treat early and late-stage cancers, including head and neck, prostate, breast, cervical, and anal. PDS Biotechnology serves patients worldwide. In May 2021, the PDS Biotechnology Corporation and Head and Neck Cancer Alliance (HNCA) announced their collaboration for the improvement of the knowledge of novel and developing treatment options for individuals with HPV-related head and neck cancer diagnoses, including available clinical trials.

Key Companies in the Head and Neck Cancer market include

• Bayer Healthcare AG


• Boston Biomedical, Inc.


• Bristol-Myers Squibb Company


• Astellas Pharma Inc.


• AbbVie Inc.


• AstraZeneca Plc.


• Acceleron Pharma Inc.


• DentalEZ, Inc.


• Koninklijke Philips N.V.


• Siemens Healthcare Private Limited


• AB Sciences


• AdDent Incorporated.

Head and Neck Cancer Industry Developments

August 2022 Genexine Inc, a clinical-stage biotechnology company involved in developing and commercializing immunotherapeutics, declared the administration of dosage to the patient in a phase II clinical trial. The company used a triple combination therapy of GX-188E (therapeutic DNA vaccine), GX-I7 (long-acting interleukin 7), and OpdivoR (nivolumab), PD-1 immune checkpoint inhibitor for the therapy of metastatic head and neck squamous cell carcinoma.

Head and Neck Cancer Market Segmentation

Head and Neck Cancer Type Outlook

• Laryngeal Cancer


• Pharyngeal Cancer


• Salivary Gland Cancer


• Lip & Oral Cavity Cancer


• Nasopharyngeal Cancer


• Others

Head and Neck Cancer Diagnosis Outlook

• Bioscopy Screening Tests


• Blood Tests


• Dental Diagnosis


• Imaging


• Endoscopy

Head and Neck Cancer Treatment Outlook

• Chemotherapy


• Surgery


• Radiation Therapy


• Targeted Therapy


• Others

Head and Neck Cancer End-User Outlook

• Hospital


• Specialty Clinics


• Ambulatory Surgical Centers


• Others

Head and Neck Cancer Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America